[Current status of thrombolysis. The need for coadjuvant antithrombotic therapy].
Thrombolytic therapy yields a 80% repermeabilitation in the acute myocardium infarct if applied soon. In other thrombotic sites such as deep venous thrombosis, pulmonary thromboembolism and peripheral arterial thrombosis, with no large cooperative randomized clinical trials, its usefulness is clear, tough selectively. The high rethrombosis frequency is the major drawback of this therapy. The concomitant use of an anti-thrombotic and/or anti-aggregant agent, even tough the possible higher risks of hemorrhages, seems a key element to improve the results obtained with thrombolysis.
García Frade
L J
LJ
Servicio de Hematología, Hospital Ramón y Cajal, Madrid.
García Avello
A
A
D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy
D005343:Fibrinolytic Agents
Estado actual de la trombolisis. Necesidad de la terapéutica antitrombótica coadyuvante.